# Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer

> **NCT00946881** · PHASE1,PHASE2 · COMPLETED · sponsor: **Steba Biotech S.A.** · enrollment: 30 (actual)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** WST 11 -mediated -VTP

## Key facts

- **NCT ID:** NCT00946881
- **Lead sponsor:** Steba Biotech S.A.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-07
- **Primary completion:** 2012-07
- **Final completion:** 2012-08
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2024-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00946881

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00946881, "Safety and Tolerability Study Using WST11 In Patients With Localized Prostate Cancer". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00946881. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*